324 results
6-K
EX-99.1
SNY
Sanofi
25 Apr 24
Sales growth of 6.7% at CER and business EPS(1) of €1.78
10:49am
the monoclonal antibodies alliance, the share of profit paid by Regeneron towards development costs and the reimbursement of commercialization-related expenses
F-3ASR
SNY
Sanofi
4 Apr 24
Automatic shelf registration (foreign)
2:07pm
to specific rules.
Taxation of Income
Interest and Other Revenues (including reimbursement premium) from the Debt Securities
French Taxation. Payments
F-3ASR
EX-25.1
SNY
Sanofi
4 Apr 24
Automatic shelf registration (foreign)
2:07pm
indemnification or advancement of expenses or other reimbursement available to the applicable director or officer (other than for coverage maintained
F-3ASR
EX-4.1
SNY
Sanofi
4 Apr 24
Automatic shelf registration (foreign)
2:07pm
. Compensation and Reimbursement.
SECTION 608. Disqualification; Conflicting Interests.
SECTION 609. Corporate Trustee Required; Eligibility.
SECTION 610 … for interest on any money received by it hereunder except as otherwise agreed upon in writing with the Company.
SECTION 607. Compensation and Reimbursement
6-K
EX-99.4
SNY
Sanofi
27 Feb 24
Current report (foreign)
11:35am
and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement of Regeneron’s Products from third … , and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payers and new policies and procedures adopted
6-K
EX-99.2
try3f2fmmmzn87n9
27 Feb 24
Current report (foreign)
11:35am
6-K
EX-99.1
5kqyqi0pk 3pgxg
2 Feb 24
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo
1:21pm
6-K
EX-99.1
5xtwba2t948qt20k
1 Feb 24
Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
9:45am
6-K
EX-99.1
epk56a3g9q
23 Jan 24
Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline
7:23am
F-6EF
EX-99
a386 llqo
18 Dec 23
Automatic registration for ADRs (foreign)
5:23pm
6-K
EX-99.1
n6e fgrz38
1 Dec 23
Current report (foreign)
12:19pm
6-K
EX-99.1
ft7dmuqx2jq8v0zkazyh
27 Oct 23
Specialty Care growth, strong launch uptake of Beyfortus® and ALTUVIIIO® drive solid Q3 results
12:39pm
6-K
EX-99.1
voxwuh45ee6mmil1
26 Oct 23
Sanofi and Regeneron provide update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria
7:16am
6-K
EX-99.2
dj3xv0z4
26 Oct 23
Sanofi and Regeneron provide update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria
7:16am
6-K
EX-99.3
p4962iwpx2is
27 Sep 23
Current report (foreign)
6:06am
6-K
EX-99.1
sfekyol
10 Aug 23
Recommendation for use in all infants below 8 months of age follows earlier than anticipated FDA approval and unanimous FDA Advisory Committee vote
9:50am
6-K
EX-99.1
yzr6tw6mp wjlkp
28 Jul 23
Solid Q2 performance and strong pipeline momentum
3:35pm
6-K
EX-99.2
ixj6g13dx ushvz0a
28 Jul 23
Condensed Half-year Consolidated Financial Statements
7:00am
6-K
EX-99.1
9toc8xawmz s0nw
28 Jul 23
Condensed Half-year Consolidated Financial Statements
7:00am
6-K
EX-99.2
48tvxqx5yf974ks
23 May 23
Current report (foreign)
1:01pm